Sahajanand Medical Technologies
Sahajanand Medical Technologies Limited is a public limited company incorporated on Oct 18, 2001, engaged in the development and manufacturing of minimally invasive coronary stent systems, headquartered in Mumbai, Maharashtra.
“Sahajanand Medical Technologies: momentum beats fundamentals — a trader's IPO, not an investor's.”
- ▸Decent demand 4.29x
- ▸Anchors took 29.4% — confident
- ▸Revenue shrinking — avoid for long term
- ▸Thin -1% margins — fragile
- ▸Profit not converting to cash — biggest red flag
- ▸2 forensic red flags in DRHP footnotes
- ⚠ The company is required to obtain, renew or maintain statutory and regulatory permits, licenses and approvals; any delay or inability could adversely affect its business, financial condition, cash flows and results of operations.
- ⚠ The company is dependent on a limited number of suppliers (top 10 suppliers contributed over 60% of purchases in recent fiscal years) and a single supplier for certain components; supply disruptions could adversely affect its business, financial condition, cash flows and results of operations.
Educational only. Not investment advice. GMP is unofficial chatter, never a promise.
Demand — who is actually bidding?
Live from NSE's official bid feed. QIB is smart money — if QIB sleeps past Day 2, listing pop usually dies.
Unofficial chatter, tracked daily — direction signal, never a promise.
Issue structure — where does money go?
- ▸Offer for sale of 2.76 crore shares
- Promoter 36.8% → 0% after IPO
Deep financials — does profit become cash?
| FY | REVENUE | PAT | MARGIN | ROE | ROCE | D/E | CFO |
|---|---|---|---|---|---|---|---|
| FY25 | ₹1035.96 Cr | ₹25.15 Cr | 2.4% | — | — | — | ₹0 Cr |
| FY26 | ₹1218.73 Cr | ₹69.08 Cr | 5.7% | — | — | — | ₹0 Cr |
| FY24 | ₹908.59 Cr | ₹-7.35 Cr | -0.8% | — | — | — | ₹0 Cr |
Valuation vs listed peers
| COMPANY | P/E | P/B | ROE |
|---|---|---|---|
| Sahajanand Medical Technologies (IPO) | — | — | -0.8% margin |
| Rays of | 56.67 | — | — |
| Molbio Diagnostics | 84.65 | — | — |
| Manipal Health | — | — | — |
Read it as: peers show what the market already pays for this business model. IPO multiples land with the RHP parse.
Risk dossier
- 01The company is required to obtain, renew or maintain statutory and regulatory permits, licenses and approvals; any delay or inability could adversely affect its business, financial condition, cash flows and results of operations.
- 02The company is dependent on a limited number of suppliers (top 10 suppliers contributed over 60% of purchases in recent fiscal years) and a single supplier for certain components; supply disruptions could adversely affect its business, financial condition, cash flows and results of operations.
Street tape
Documents & filings
Primary sources — the same PDFs our dossier numbers come from.
Questions investors ask about Sahajanand Medical Technologies
Should I apply for the Sahajanand Medical Technologies IPO for listing gains?
Only if Day-2 QIB crosses 5x — otherwise the listing setup is weak.
Is Sahajanand Medical Technologies good for the long term?
Not yet — wait for cheaper re-entry or cleaner quarters.
What is the Sahajanand Medical Technologies IPO price band and lot size?
₹327–₹344, lot of 43 shares (min ₹14,792). Open 15 Oct 2026 to 19 Oct 2026.
How do I check Sahajanand Medical Technologies IPO allotment status?
On the MUFG Intime India Pvt.Ltd. portal: select Sahajanand Medical Technologies, enter PAN, application number, or DP/Client ID, solve the captcha. Results go live 6–10 PM on allotment evening (issue closed 19 Oct 2026). BSE's application-status page works as fallback.
When is the Sahajanand Medical Technologies listing date?
Tentatively 23 Oct 2026 (T+3 after close).
Who should apply?
- • Listing trader → yes, momentum is real
- • Long-term holder → wait for cheaper re-entry
- • First-time investor → learn by watching, not betting
Listing-day playbook
- • Opens +40%↑ → book half, keep rest at cost stop
- • Opens flat ±5% → hold only if long-term score ≥7
- • Opens discount → never average down Day 1